Efgartigimod for severe myasthenia gravis flare-ups
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a drug called efgartigimod (given through an IV) to see if it can help people who are in a myasthenic crisis — a severe flare-up of myasthenia gravis that makes it hard to breathe. The goal is to help patients recover faster from this dangerous worsening of symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18.
- You have a confirmed diagnosis of generalized myasthenia gravis (muscle weakness that affects more than just your eyes).
- You are currently having a myasthenic crisis — a severe worsening of weakness that makes it hard to breathe, or that requires a breathing tube.
- You have antibodies to AChR or MuSK (a blood test can check this).
- You have not used efgartigimod before and are not allergic to it.
- If you are male, you agree to use effective birth control during the study; if you are female, you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Hear when a new Myasthenia Gravis Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.